Fuda Institute of Cryosurgery for Cancer

Tianhe District, China

Fuda Institute of Cryosurgery for Cancer

Tianhe District, China

Time filter

Source Type

Niu L.,Jinan University | Niu L.,Fuda Institute of Cryosurgery for Cancer | Chen J.,Jinan University | Yao F.,Jinan University | And 17 more authors.
Cryobiology | Year: 2013

The aim of this study was to investigate the therapeutic effect of cryoablation treatment and palliative treatment in stage IV lung cancer. Fifty-four patients were enrolled into the study. Thirty-one patients received cryoablation treatment (including intra- and extrapulmonary tumors), and 23 patients had palliative treatment (no cryoablation). Both the safety of the procedure and overall survival (OS) for stage IV lung cancer were assessed during a 6.5. year follow-up period. The OS of patients in both groups and the effects of treatment timing and frequency were compared. The OS in the cryoablation group was significantly longer than in the palliative group (median OS: 14. months vs. 7. months, P= 0.0009). The OS of those who received delayed cryoablation treatment was longer than that observed for those who received timely treatment (median OS: 18.5. months vs. 10. months, P= 0.0485), but this was not observed in those who received palliative treatment (median OS: 7. months vs. 7.5. months, P= 0.9814). Multiple treatments played an important role in improving the OS of patients who received cryoablation treatment (median OS: 18. months vs. 14. months, P= 0.0376). There was a significant difference between cryoablation and palliative treatment, in terms of OS. In addition, multiple cryoablation treatments may have an advantage over single treatments. © 2013 Elsevier Inc.


Niu L.,Jinan University | Niu L.,Fuda Institute of Cryosurgery for Cancer | Wang Y.,Jinan University | Yao F.,Jinan University | And 9 more authors.
Cryobiology | Year: 2013

Little is known about the effects of pancreas cryoablation (PCA) on abdominalgia in pancreatic cancer patients or its synergism with celiac plexus block (CPB). In patients without abdominalgia, to investigate the effects of PCA; in patients with abdominalgia, to investigate the pain-alleviating effects of PCA. +. CPB. Sixty-two patients were enrolled in this retrospective review; 12 without abdominalgia refused PCA, 15 without abdominalgia received PCA to reduce their tumor load and 35 with abdominalgia received PCA. +. CPB to reduce tumor load and alleviate pain. All PCA and PCA. +. CPB procedures were performed successfully. Some slight adverse effects (e.g. increased serum amylase, abdominal distension and nausea, abdominal bleeding) had disappeared by 3. weeks, spontaneously or after symptomatic treatment. In patients without abdominalgia, pain occurred in one-third of cases (all with pancreatic head cancer) after PCA but had stopped 1-12. days after treatment; in patients with abdominalgia before treatment, pain stopped immediately after PCA. +. CPB in 18 cases and 2-24. days after treatment in 17 (all with pancreatic head cancer); a significant difference was found between pretreatment and post-treatment pain frequency (. P=. 0.0019), regardless of the presence of advanced (. P=. 0.0096) or metastatic (. P=. 0.0072) cancer. The average time to pain relief was approximately 7. days after both PCA and PCA. +. CPB, and abdominalgia did not recur for more than 8. weeks. PCA may cause short-term pain in some pancreatic cancer patients. Combined PCA. +. CPB can alleviate cancer pain for more than 8. weeks, without severe side effects. © 2012 Elsevier Inc.


Yuanying Y.,Jinan University | Lizhi N.,Jinan University | Lizhi N.,Fuda Institute of Cryosurgery for Cancer | Feng M.,Fuda Institute of Lung Cancer | And 13 more authors.
Cryobiology | Year: 2013

Currently there are no effective therapies for the treatment of metastatic non-small cell lung cancer (NSCLC). Here, we conducted a retrospective study of 161 patients to evaluate the therapeutic effects of combining cryosurgery, chemotherapy and dendritic cell-activated cytokine-induced killer cells (DC-CIK) immunotherapy. The overall survival (OS) after diagnosis of metastatic NSCLC to patient death was assessed during a 5-years follow-up period. OS of patients who received comprehensive cryotherapy was (median OS, 20. months; n= 86) significantly longer than that of patients who did not received cryotherapy (median OS, 10. months; n= 75; P<. 0.0001). Five treatment combinations were selected: chemotherapy (n= 44); chemo-immunotherapy (n= 31); cryo-chemotherapy (n= 32); cryo-immunotherapy (n= 21); and cryo-chemo-immunotherapy (n= 33). A combination of cryotherapy with either chemotherapy or immunotherapy lead to significantly longer OS (18. months and 17. months, respectively) compared to chemotherapy and chemo-immunotherapy (8.5. months and 12. months, respectively; P<. 0.001); however, the median OS of patients who underwent cryo-chemo-immunotherapy was significantly longer (27. months) compared to the other treatment programs (P<. 0.001). In conclusion, a combination of cryotherapy, chemotherapy and DC-CIK immunotherapy proved the best treatment option for metastatic NSCLC in this group of patients. © 2013 Elsevier Inc.


Shi J.,Jinan University | Niu L.,Jinan University | Niu L.,Fuda Institute of Cryosurgery for Cancer | Huang Z.,Jinan University | And 7 more authors.
Cryobiology | Year: 2013

Coagulopathy after liver cryoablation was first reported many years ago; the cause is local platelet trapping and destruction within the margin of the cryolesion. However, the prognosis and therapeutic effects of coagulopathy remain unclear. This study retrospectively reviewed clinical data from 372 patients (525 sessions) who underwent liver cryoablation in our hospital during the past 4.5years. Small tumors (major diameter<6cm) were treated with a single complete ablation; massive tumors (major diameter 6-10cm or >10cm) were divided into two or three parts that were dealt with in turn. Platelet counts decreased to an average of (46.12±68.13)×109/L after each session of cryoablation. The decline was most evident in patients with high pretreatment platelet counts, while those with low pretreatment counts had the highest risk of coagulopathy. Change in platelet count was not correlated with the diameter of the tumor. Slight coagulopathy (platelet count (70-100)×109/L) can resolve without treatment within 1week and administration of recombinant human interleukin-11 can assist recovery from severe coagulopathy (platelet count<70×109/L). © 2013 Elsevier Inc.


Zhikai Z.,Jinan University | Lizhi N.,Jinan University | Lizhi N.,Fuda Institute of Lung Cancer | Liang Z.,Jinan University | And 10 more authors.
Cryobiology | Year: 2013

Most patients with central type lung cancer (CTLC) are not candidates for surgery; systemic chemotherapy and external beam radiotherapy are the main treatments but have not greatly affected patient outcome. Combined percutaneous and endobronchial cryotherapy has been used successfully to treat CTLC; this study aimed to determine its feasibility and safety. Forty-seven patients with unresectable CTLC (22 endotracheal, 26 tracheal wall and 21 extratracheal tumors) underwent 69 sessions of combined percutaneous cryosurgery, endobronchial cryosurgery and airway stenting. The long diameter of all tumors was <5. cm. Biopsy showed non-small cell lung cancer (NSCLC) in 40 patients (medium or well differentiated in 20 cases, poorly differentiated in 20) and small cell lung cancer (SCLC) in seven. Within 3. days after treatment, ventilatory capacity and performance status had obviously increased and cough, signs of dyspnea, hemoptysis and atelectasis improved significantly, but symptoms of pneumothorax and pleural effusion emerged. After 2. weeks, all complications had disappeared completely, as had cough. Progression-free survival (PFS) for endotracheal tumors (8. ±. 4. months) was shorter than that for tracheal wall (13. ±. 6. months, P<. 0.05) and extratracheal (14. ±. 8. months, P<. 0.01) tumors. The PFS of NSCLC (11. ±. 5. months) was significantly longer than that of SCLC (4. ±. 2. months, P<. 0.0001). The PFS of medium or well differentiated CTLC (15. ±. 8. months) was significantly longer than that of poorly differentiated CTLC (7. ±. 3. months, P<. 0.0001). In conclusion, combined cryotherapy is a safe and effective treatment for CTLC, with PFS largely influenced by tumor location and pathologic type. © 2013 Elsevier Inc.


Zhang Z.,Jinan University | Wu B.,Jinan University | Wu B.,Fuda Institute of Cryosurgery for Cancer | Niu L.,Jinan University | And 11 more authors.
Cryobiology | Year: 2013

Thymomas are the most common tumors of the mediastinum. These tumors often compress vital mediastinal organs and severely impact the quality of life of thymoma patients. To avoid the side effects of chemoradiotherapy, some patients with unresectable malignant thymomas have opted to undergo cryotherapy in our hospital. We reviewed the cryosurgery, nursing and follow-up records of our hospital for the past 8. years, and evaluated the safety and efficiency of cryotherapy in 19 patients with unresectable malignant thymomas. No severe complications involving the vital organs surrounding the tumor occurred during or after cryosurgery. The most common side effect was pleural effusion, which occurred in 11 patients and healed after drainage within 1. week. Cough, mediastinal and pericardial effusions, pneumothorax, mild fever and chest tightness also occurred and resolved 1. week after symptomatic treatment. Since our patients had high KPS scores and mild myasthenia gravis symptoms before the treatment, myasthenia gravis did not occur after the treatment. The progression-free survival of the patients was 14-29. months (median, 18. months), and did not differ between patients with large tumors and those with small tumors (P= 0.6753). In conclusion, cryotherapy is a safe and efficient method for the treatment of unresectable malignant thymoma. © 2013 Elsevier Inc.


Mu F.,Chinese Academy of Sciences | Niu L.,Jinan University | Niu L.,Fuda Institute of Cryosurgery for Cancer | Li H.,Chinese Academy of Sciences | And 11 more authors.
Cryobiology | Year: 2013

Percutaneous ablation is the currently preferred locoregional therapy for non-resectable hepatocellular cancer (HCC). Cryoablation is an attractive option because it forms an ice ball viewable by many imaging methods. This study assessed the therapeutic effect of comprehensive cryoablation (of intra- and extrahepatic tumors) in patients with metastatic HCC. Forty-five patients met the inclusion criteria from January, 2004 to October, 2011. Treatment was performed on 33 patients; 12 patients received no treatment. Procedural safety and overall survival (OS) were assessed according to metastatic stage. The OS of patients who received comprehensive treatment was significantly longer than that of those who received no treatment (median: 26 vs. 3.5. months, P<. 0.001). Large (5. cm long diameter) hepatic tumors were treated in advance with transarterial chemoembolization, but the OS of patients in the same metastatic stage was similar (. P=. 0.0677). In the comprehensive cryoablation group, timely treatment (within 2. months after diagnosis of metastatic HCC) was associated with a longer OS than when treatment was delayed for 3-7. months (median: 38.5 vs. 21. months, P=. 0.0167). Multiple treatments improved the survival of patients who received comprehensive treatment (. P=. 0.0489). In terms of increasing the survival time of metastatic HCC patients, the effect of comprehensive cryosurgery was significant. Timely or multiple treatments had greater therapeutic effects than delayed or single treatment. © 2012 Elsevier Inc.


Niu L.-Z.,Jinan University | Niu L.-Z.,Fuda Institute of Cryosurgery for Cancer | Li J.-L.,Jinan University | Li J.-L.,Fuda Institute of Cryosurgery for Cancer | And 14 more authors.
World Journal of Gastroenterology | Year: 2013

AIM: To retrospectively assess the effect of comprehensive cryosurgery (ablation of intra-and extra-hepatic tumors) plus dendritic cell-cytokine-induced killer cell immunotherapy in metastatic hepatocellular cancer. METHODS: We divided 45 patients into cryo-immunotherapy (21 patients), cryotherapy (n = 12), immunotherapy (n = 5) and untreated (n = 7) groups. Overall survival (OS) after diagnosis of metastatic hepatocellular cancer was assessed after an 8-year follow-up. RESULTS: Median OS was higher following cryo-immunotherapy (32 mo) or cryotherapy (17.5 mo; P < 0.05) than in the untreated group (3 mo) and was higher in the cryo-immunotherapy group than in the cryotherapy group (P < 0.05). In the cryo-immunotherapy group, median OS was higher after multiple treatments (36.5 mo) than after a single treatment (21 mo; P < 0.05). CONCLUSION: Cryotherapy and, especially, cryoimmunotherapy significantly increased OS in metastatic hepatocellular cancer patients. Multiple cryo-immunotherapy was associated with a better prognosis than single cryo-immunotherapy. © 2013 Baishideng. All rights reserved.


Niu L.,Jinan University | Niu L.,Fuda Institute of Cryosurgery for Cancer | Li J.,Jinan University | Zeng J.,Jinan University | And 7 more authors.
Cryobiology | Year: 2014

We compared imaging and pathological changes between argon-helium cryosurgical (AH) and microwave (MW) ablation in a porcine liver model. Immediately after ablation, computed tomography (CT) imaging showed that the area affected by MW ablation was considerably greater than that affected by AH ablation; moreover, the surface area of necrotic tissue was considerably greater in the AH group, whereas the depth of the necrotic area was similar. Seven days after ablation, the affected area had not changed much in the AH group, but it had significantly increased in the MW group; similarly, the surface and depth of the necrotic areas had not changed much in the AH group, but they had increased significantly in the MW group. The pathological findings showed similar definitive areas for both groups at both time points. The findings indicated that long time after both therapies, complete tissue necrosis can be achieved, but the extent and depth of necrosis differ: necrosis foci after AH ablation could be predicted by ice ball under CT image, and necrosis foci after MW ablation will increase obviously. MW ablation might therefore be suitable for tumors with a larger volume and simple anatomical structures, and AH ablation might be suitable for tumors with complex anatomical structures or those located near important organs. These two methods could therefore be used in combination in clinical settings, but details of the procedure need to be studied. © 2014 Elsevier Inc.


Ali A.M.A.,Huazhong University of Science and Technology | Lizhi N.,Fuda Cancer Hospital | Lizhi N.,Fuda Institute of Cryosurgery for Cancer | Jialiang L.,Fuda Cancer Hospital | And 11 more authors.
Cryobiology | Year: 2014

Percutaneous cryoablation is a potentially curative treatment for hepatocellular carcinoma (HCC). After liver cryosurgery, rapid elevations of transaminases and bilirubin are common, but are usually transient and normalize within a few days. This study retrospectively reviewed clinical data from 51 patients who underwent liver cryoablation in our hospital during the past 4.5. years. Sixty-six percutaneous cryoablations were performed in these patients and transaminase and bilirubin levels before and after the procedure were observed. Although most patients received liver-protective treatment before cryosurgery, transaminase levels were double (mean alanine transaminase (ALT) and aspartate transaminase (AST) were 71. U/L and 85. U/L, respectively) the normal ranges in our hospital. One day after cryosurgery, ALT and AST had increased 3.3-fold (peak mean was 241. U/L) and 5-fold (peak mean was 427. U/L), respectively, but were close to the preoperative level 5. days post-cryosurgery. No significant increase of serum bilirubin was observed. Serum transaminase and bilirubin levels were compared between hepatitis B positive and hepatitis B negative patients. Only in the hepatitis B positive group were total bilirubin (74. μmol/L/23. μmol/L = 3.2) and direct bilirubin (45. μmol/L/12. μmol/L = 3.8) more than 3. times the preoperative level 7-9. days after treatment. Overall, ALT and AST are valuable as indicators of liver function impairment following cryosurgery. In patients with hepatitis B virus, serum bilirubin was 3. times the preoperative level 7-9. days after cryosurgery. Liver-protective treatment may alleviate liver function impairment due to cryosurgery. © 2014 Elsevier Inc.

Loading Fuda Institute of Cryosurgery for Cancer collaborators
Loading Fuda Institute of Cryosurgery for Cancer collaborators